skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Pharmacogenomics of drug efficacy in the interferon treatment of chronic hepatitis C using classification algorithms

Original Research

(2489) Views  (694) Full article downloads

Authors: Wan-Sheng Ke, Yuchi Hwang, Eugene Lin

Published Date June 2010 Volume 2010:3 Pages 39 - 44
DOI: http://dx.doi.org/10.2147/AABC.S8656

Wan-Sheng Ke1, Yuchi Hwang2, Eugene Lin2

1Department of Internal Medicine, Kuang Tien General Hospital, Taichung County, Taiwan; 2Vita Genomics, Inc., Jung-Shing Road, Wugu Shiang, Taipei, Taiwan

Abstract: Chronic hepatitis C (CHC) patients often stop pursuing interferon-alfa and ribavirin (IFN-alfa/RBV) treatment because of the high cost and associated adverse effects. It is highly desirable, both clinically and economically, to establish tools to distinguish responders from nonresponders and to predict possible outcomes of the IFN-alfa/RBV treatments. Single nucleotide polymorphisms (SNPs) can be used to understand the relationship between genetic inheritance and IFN-alfa/RBV therapeutic response. The aim in this study was to establish a predictive model based on a pharmacogenomic approach. Our study population comprised Taiwanese patients with CHC who were recruited from multiple sites in Taiwan. The genotyping data was generated in the high-throughput genomics lab of Vita Genomics, Inc. With the wrapper-based feature selection approach, we employed multilayer feedforward neural network (MFNN) and logistic regression as a basis for comparisons. Our data revealed that the MFNN models were superior to the logistic regression model. The MFNN approach provides an efficient way to develop a tool for distinguishing responders from nonresponders prior to treatments. Our preliminary results demonstrated that the MFNN algorithm is effective for deriving models for pharmacogenomics studies and for providing the link from clinical factors such as SNPs to the responsiveness of IFN-alfa/RBV in clinical association studies in pharmacogenomics.

Keywords: chronic hepatitis C, artificial neural networks, interferon, pharmacogenomics, ribavirin, single nucleotide polymorphisms






 

Other articles by Dr Eugene Lin



Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Classification of heterodimer interfaces using docking models and construction of scoring functions for the complex structure prediction
Computer applications for prediction of protein–protein interactions and rational drug design
Ego mechanisms of defense are associated with patients’ preference of treatment modality independent of psychological distress in end-stage renal disease
Can a gentamicin-specific chart reduce neonatal medication errors?
Predicting recurrent aphthous ulceration using genetic algorithms-optimized neural networks
Nephroprotective action of glycosaminoglycans: why the pharmacological properties of sulodexide might be reconsidered
Dashboards in neonatology
Construction of random perfect phylogeny matrix
Everolimus-eluting stents: update on current clinical studies
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University